Current chemotherapy of human African trypanosomiasis
Current chemotherapy of human African trypanosomiasis
复制标题
DOI：
10.1007/s00436-002-0752-y
复制
发表时间：
2003-06-01
影响因子：
2
通讯作者：
Moreno, SNJ
中科院分区：
文献类型：
--
作者：
Docampo, R;Moreno, SNJ
非洲人类锥虫病是由近年来再次出现的冈比亚布氏锥虫和罗得西亚布氏锥虫引起的一种致命疾病。然而，在开发针对这种疾病的新药方面进展甚微。目前仍在使用的大多数药物都是在十几年前开发出来的，通常是有毒的，而且效果有限。最近引进的化合物依氟鸟氨酸仅对由布氏冈比亚锥虫引起的昏睡病有效，而且对非洲发展中国家来说过于昂贵。我们在这里概述了今天批准的和临床使用的治疗这种疾病的药物。
Human African trypanosomiasis is a fatal disease caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense that has re-emerged in recent years. However, very little progress has been made in the development of new drugs against this disease. Most drugs still in use were developed one or more decades ago, and are generally toxic and of limited effectiveness. The most recently introduced compound, eflornithine, is only useful against sleeping sickness caused by T. b. gambiense, and is prohibitively expensive for the African developing countries. We present here an overview of today's approved and clinically used drugs against this disease.